PTPRF Specific Neutra™ Antibody Products

Are your oncology or metabolic disease studies hindered by poor target validation or unreliable antibody performance? Creative Biolabs' PTPRF-specific Neutra™ antibody products use innovative epitope mapping and structural biology insights to deliver validated antibodies that enable precise modulation of PTPRF signaling, accelerating therapeutic development.

Introduction to PTPRF

Protein tyrosine phosphatase receptor type F (PTPRF), also known as leukocyte antigen-related phosphatase (LAR PTP), is a transmembrane tyrosine phosphatase that regulates cellular signaling by dephosphorylating key substrates. It is critical for maintaining equilibrium in pathways governing cell adhesion, growth, and metabolism.

• Basic Information

PTPRF is a type III receptor protein tyrosine phosphatase. It features an extracellular ligand-binding domain, a transmembrane region, and two cytoplasmic phosphatase domains. Highly expressed in tissues such as the brain, pancreas, and epithelial cells, PTPRF modulates insulin receptor signaling, receptor tyrosine kinase (RTK) activity, and cadherin-mediated cell-cell adhesion. Its dysregulation is implicated in cancer progression, diabetes, and neurological disorders.

• Structure

The extracellular segment of PTPRF contains three immunoglobulin-like domains and eight fibronectin type III repeats, enabling interactions with extracellular ligands like pleiotrophin and contactin. The intracellular catalytic domains (D1 and D2) dephosphorylate tyrosine residues on RTKs (e.g., IGF-1R, EGFR) and β-catenin, directly influencing downstream signaling cascades. Structural studies reveal that PTPRF's phosphatase activity requires conformational activation via ligand binding, making it a mechanistically complex therapeutic target.

Fig.1 PTPRF protein structure and alternative splicing sites.^1,2

• Related Signaling Pathways

PTPRF antagonizes insulin signaling by dephosphorylating the insulin receptor, reducing glucose uptake and contributing to insulin resistance. In cancer, it promotes tumor cell survival by suppressing apoptosis through RTK dephosphorylation. Additionally, PTPRF stabilizes cadherin-catenin complexes at adherens junctions, thereby preserving epithelial integrity.

• Pathologies

Overexpression of PTPRF is linked to metastasis in colorectal, breast, and pancreatic cancers due to enhanced cell migration and invasion. Conversely, reduced PTPRF activity correlates with insulin resistance and type 2 diabetes. Emerging evidence also associates PTPRF polymorphisms with autism spectrum disorders, highlighting its neurodevelopmental significance.

Fig.2 PTPRF participates in several neural functions.^1,3

Applications of Anti-PTPRF Neutralizing Antibodies

• Cancer Therapeutics Development

Anti-PTPRF antibodies inhibit tumor growth and metastasis by reactivating RTK-mediated apoptosis pathways. Preclinical models demonstrate reduced proliferation in PTPRF-overexpressing colon cancer xenografts, supporting their potential as antibody-drug conjugates (ADCs).

• Diabetes and Metabolic Disease Management

By blocking PTPRF's interaction with insulin receptors, these antibodies enhance insulin sensitivity in in vitro hepatocyte models, offering a novel approach to counteract metabolic syndrome.

• Neurological Disorder Research

Antibody-mediated PTPRF inhibition reverses synaptic deficits in autism-related neuronal cultures, providing tools to explore neurodevelopmental processes.

• Companion Diagnostics

High-specificity anti-PTPRF antibodies enable quantitative detection of PTPRF isoforms in patient sera, aiding prognosis in epithelial cancers.

Our Anti-PTPRF Antibodies

Creative Biolabs' PTPRF-specific Neutra™ antibody products combine rigorous validation and customizable formats to empower your drug discovery pipeline. Our PTPRF-specific antibodies are engineered to block ligand-receptor interactions or inhibit phosphatase activity, offering dual mechanisms for functional studies:

- Neutralizing antibodies bind the extracellular Ig-like domains, preventing ligand-induced activation and subsequent downstream signaling.

- Catalytic inhibitors target intracellular phosphatase domains to restore RTK or β-catenin phosphorylation, reversing oncogenic or metabolic phenotypes.

Validated in ELISA, IHC, and co-immunoprecipitation assays, these antibodies exhibit >95% purity and high batch-to-batch consistency. Applications include drug screening, biomarker validation, and preclinical model development.

Contact our scientific team today to discuss your project needs and request product specifications.

REFERENCES

1. Cornejo, Francisca, et al. "LAR receptor tyrosine phosphatase family in healthy and diseased brain." Frontiers in Cell and Developmental Biology 9 (2021): 659951. https://doi.org/10.3389/fcell.2021.659951
2. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image.
3. Distributed under Open Access license CC BY 4.0, without modification.